Beyond Celiac is the leading trusted resource on celiac disease. We are available and qualified to speak to the press on a variety of topics including, but not limited to:
- Celiac disease as a serious genetic autoimmune disease
- Health equity in celiac disease
- Celiac disease patient advocacy and patient stories
- The need for treatments beyond the gluten-free diet
- The latest in celiac disease research/science/drug development
- Non-GI symptoms of celiac disease
- Connection to other autoimmune diseases
- Growth of the gluten-free market, gluten-free labeling
Media Inquiries and Partnerships
If you are a member of the media and want to know more about Beyond Celiac, including our research program, Science Plan, patient stories, and more, please contact Stacy Eaton-Carter at [email protected].
Celiac Disease Facts and Information
Check out the resources below for more information on Beyond Celiac, celiac disease and the gluten-free diet:
About Beyond Celiac
Download Founder Alice Bast’s Headshots
Beyond Celiac Brand Elements/Logos
Download Celiac Disease: The Basics (including the gluten-free diet)
Fast Facts about Celiac Disease
Download Fact vs Fiction: Celiac Disease and the Gluten-Free Diet
Read the Beyond Celiac Science Plan
Read stories from real patients in our Voces de la enfermedad celíaca archive
Articles from Beyond Celiac
Beyond Celiac Launches First Investment Program for Celiac Disease Therapeutics
Beyond Celiac, the leading catalyst for a cure for celiac disease, today announces the creation of Beyond Celiac Investments (BCI), an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets.
Beyond Celiac Launches First Investment Program for Celiac Disease Therapeutics
Beyond Celiac announces the creation of Beyond Celiac Investments (BCI), an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets. BCI launches with an initial funding of $2 million and additional capital will be raised through donations.
Beyond Celiac in the News
-
Quoted
Teva’s Lab-Made Antibody Shot for Celiac Shows Hopeful Results (opens in a new tab)
Allergic Living
-
Quoted
With 3 Federal Bills in Play, Hopes are High for Full Gluten Labeling (opens in a new tab)
Allergic Living
-
Subject
Philadelphia cell therapy company raises $15.1M with local backing (opens in a new tab)
Business Journal